Mitochondrial dysfunction in the striatum of aged chronic mouse model of Parkinson's disease

Frontiers in Aging Neuroscience

Volumn 1, Issue DEC, 2009, Pages

  Patki, Gaurav ^a   Che, Yi ^a   Lau, Yuen Sum ^a  

^a UNIVERSITY OF HOUSTON   (United States)

Author keywords

Age related; Chronic animal model; Mitochondrial defects; Neurodegeneration; Parkinson's disease

Indexed keywords

EID: 79953293026     PISSN: None     EISSN: 16634365     Source Type: Journal    
DOI: 10.3389/neuro.24.003.2009     Document Type: Article

References (52)

1. Ali, S. F., David, S. N., Newport, G. D., Cadet, J. L., and Slikker, W. Jr. (1994). MPTP-induced oxidative stress and neurotoxicity are age-dependent: evidence from measures of reactive oxygen species and striatal dopamine levels. Synapse 18, 27-34.
2. Arduino, D. M., Esteves, A. R., Oliveira, C. R., and Cardoso, S. M. (2009). Mitochondrial metabolism modulation: a new therapeutic approach for Parkinson's disease. CNS Neurol. Disord. Drug Targets. [Epub ahead of print].
3. Arnheim, N., and Cortopassi, G. (1992). Deleterious mitochondrial DNA mutations accumulate in aging human tissues. Mutat. Res. 275, 157-167.
4. Barber-Singh, J., Seo, B. B., Nakamaru-Ogiso, E., Lau, Y. S., Matsuno-Yagi, A., and Yagi, T. (2009). Neuroprotective effect of long-term NDI1 gene expression in a chronic mouse model of Parkinson disorder. Rejuvenation Res. 12, 259-267.
5. Beal, M. F. (2005). Mitochondria take center stage in aging and neurodegeneration. Ann. Neurol. 58, 495-505.
6. Bender, A., Krishnan, K. J., Morris, C. M., Taylor, G. A., Reeve, A. K., Perry, R. H., Jaros, E., Hersheson, J. S., Betts, J., Klopstock, T., Taylor, R. W., and Turnbull, D. M. (2006). High levels of mitochondrial DNA deletions in substantia nigra neurons in aging and Parkinson disease. Nat. Genet. 38, 515-517.
7. Bertoni-Freddari, C., Fattoretti, P., Giorgetti, B., Solazzi, M., Balietti, M., and Meier-Ruge, W. (2004). Role of mitochondrial deterioration in physiological and pathological brain aging. Gerontology 50, 187-192.
8. Betarbet, R., Sherer, T. B., MacKenzie, G., Garcia-Osuna, M., Panov, A. V., and Greenamyre, J. T. (2000). Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat. Neurosci. 3, 1301-1306.
9. Blum, D., Torch, S., Lambeng, N., Nissou, M., Benabid, A. L., Sadoul, R., and Verna, J. M. (2001). Molecular pathways involved in the neurotoxicity of 6-OHDA, dopamine and MPTP: contribution to the apoptotic theory in Parkinson's disease. Prog. Neurobiol. 65, 135-172.
10. Bronstein, J., Carvey, P., Chen, H., Cory-Slechta, D., DiMonte, D., Duda, J., English, P., Goldman, S., Grate, S., Hansen, J., Hoppin, J., Jewell, S., Kamel, F., Koroshetz, W., Langston, J. W., Logroscino, G., Nelson, L., Ravina, B., Rocca, W., Ross, G. W., Schettler, T., Schwarzschild, M., Scott, B., Seegal, R., Singleton, A., Steenland, K., Tanner, C. M., Van Den Eeden, S., and Weisskopf, M. (2009). Meeting report: consensus statement-Parkinson's disease and the environment: collaborative on health and the environment and Parkinson's Action Network (CHE PAN) conference 26-28 June 2007. Environ. Health Perspect. 117, 117-121.
11. Calabrese, V., Scapagnini, G., Giuffrida Stella, A. M., Bates, T. E., and Clark, J. B. (2001). Mitochondrial involvement in brain function and dysfunction: relevance to aging, neurodegenerative disorders and longevity. Neurochem. Res. 26, 739-764.
12. Chan, D. C. (2006). Mitochondria: dynamic organelles in disease, aging, and development. Cell 125, 1241-1252.
13. Crompton, M. (2004). Mitochondria and aging: a role for the permeability transition? Aging Cell 3, 3-6.
14. Dauer, W., Kholodilov, N., Vila, M., Trillat, A. C., Goodchild, R., Larsen, K. E., Staal, R., Tieu, K., Schmitz, Y., Yuan, C. A., Rocha, M., Jackson-Lewis, V., Hersch, S., Sulzer, D., Przedborski, S., Burke, R., and Hen, R. (2002). Resistance of alpha-synuclein null mice to the parkinsonian neurotoxin MPTP. Proc. Natl. Acad. Sci. U.S.A. 99, 14524-14529.
15. Dawson, T. M., and Dawson, V. L. (2003). Molecular pathways of neurodegeneration in Parkinson's disease. Science 302, 819-822.
16. DiMauro, S., and Schon, E. A. (2008). Mitochondrial disorders in the nervous system. Annu. Rev. Neurosci. 31, 91-123.
17. Ekstrand, M. I., Terzioglu, M., Galter, D., Zhu, S., Hofstetter, C., Lindqvist, E., Thams, S., Bergstrand, A., Hansson, F. S., Trifunovic, A., Hoffer, B., Cullheim, S., Mohammed, A. H., Olson, L., and Larsson, N. G. (2007). Progressive Parkinsonism in mice with respiratory-chain- defi cient dopamine neurons. Proc. Natl. Acad. Sci. U.S.A. 104, 1325-1330.
18. Filosto, M., Tomelleri, G., Tonin, P., Scarpelli, M., Vattemi, G., Rizzuto, N., Padovani, A., and Simonati, A. (2007). Neuropathology of mitochondrial diseases. Biosci. Rep. 27, 23-30.
19. Floor, E., and Wetzel, M. G. (1998). Increased protein oxidation in human substantia nigra pars compacta in comparison with basal ganglia and prefrontal cortex measured with an improved dinitrophenylhydrazine assay. J. Neurochem. 70, 268-275.
20. Gash, D. M., Rutland, K., Hudson, N. L., Sullivan, P. G., Bing, G., Cass, W. A., Pandya, J. D., Liu, M., Choi, D. Y., Hunter, R. L., Gerhardt, G. A., Smith, C. D., Slevin, J. T., and Prince, T. S. (2008). Trichloroethylene: Parkinsonism and complex 1 mitochondrial neurotoxicity. Ann. Neurol. 63, 184-192.
21. Gu, G., Reyes, P. E., Golden, G. T., Woltjer, R. L., Hulette, C., Montine, T. J., and Zhang, J. (2002). Mitochondrial DNA deletions/rearrangements in Parkinson disease and related neurodegenerative disorders. J. Neuropathol. Exp. Neurol. 61, 634-639.
22. Hsu, L. J., Sagara, Y., Arroyo, A., Rockenstein, E., Sisk, A., Mallory, M., Wong, J., Takenouchi, T., Hashimoto, M., and Masliah, E. (2000). Alphasynuclein promotes mitochondrial deficit and oxidative stress. Am. J. Pathol. 157, 401-410.
23. Jones, T. T., and Brewer, G. J. (2009). Critical age-related loss of cofactors of neuron cytochrome C oxidase reversed by estrogen. Exp. Neurol. 215, 212-219.
24. Kang, D., and Hamasaki, N. (2005). Alterations of mitochondrial DNA in common diseases and disease states: aging, neurodegeneration, heart failure, diabetes, and cancer. Curr. Med. Chem. 12, 429-441.
25. Klivenyi, P., Siwek, D., Gardian, G., Yang, L., Starkov, A., Cleren, C., Ferrante, R. J., Kowall, N.W., Abeliovich, A., and Beal, M.F. (2006). Mice lacking alpha-synuclein are resistant to mitochondrial toxins. Neurobiol. Dis. 21, 541-548.
26. Kraytsberg, Y., Kudryavtseva, E., McKee, A. C., Geula, C., Kowall, N. W., and Khrapko, K. (2006). Mitochondrial DNA deletions are abundant and cause functional impairment in aged human substantia nigra neurons. Nat. Genet. 38, 518-520.
27. Langston, J. W., Ballard, P., Tetrud, J. W., and Irwin, I. (1983). Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science 219, 979-980.
28. Lau, Y. S. (2005). Progressive neurodegeneration in the MPTP/probenecid model of Parkinson's disease. In Parkinson's Disease, M. Ebadi R. and Pfeiffer, eds (Boca Raton, FL, CRC Press), pp. 109-115.
29. Lau, Y. S., Novikova, L., and Roels, C. (2005). MPTP treatment in mice does not transmit and cause Parkinsonian neurotoxicity in non-treated cagemates through close contact. Neurosci. Res. 52, 371-378.
30. Lau, Y. S., Trobough, K. L., Crampton, J. M., and Wilson, J. A. (1990). Effects of probenecid on striatal dopamine depletion in acute and long-term 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated mice. Gen. Pharmacol. 21, 181-187.
31. Mann, V. M., Cooper, J. M., Krige, D., Daniel, S. E., Schapira, A. H., and Marsden, C. D. (1992). Brain, skeletal muscle and platelet homogenate mitochondrial function in Parkinson's disease. Brain 115(Pt. 2), 333-342.
32. Martin, L. J. (2006). Mitochondriopathy in Parkinson disease and amyotrophic lateral sclerosis. J. Neuropathol. Exp. Neurol. 65, 1103-1110.
33. McCord, J. M. (1993). Human disease, free radicals, and the oxidant/antioxidant balance. Clin. Biochem. 26, 351-357.
34. Meredith, G. E., Totterdell, S., Petroske, E., Santa Cruz, K., Callison, R. C. Jr., and Lau, Y. S. (2002). Lysosomal malfunction accompanies alpha-synuclein aggregation in a progressive mouse model of Parkinson's disease. Brain Res. 956, 156-165.
35. Novikova, L., Garris, B. L., Garris, D. R., and Lau, Y. S. (2006). Early signs of neuronal apoptosis in the substantia nigra pars compacta of the progressive neurodegenerative mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/ probenecid model of Parkinson's disease. Neuroscience 140, 67-76.
36. Parker, W. D. Jr., Boyson, S. J., and Parks, J. K. (1989). Abnormalities of the electron transport chain in idiopathic Parkinson's disease. Ann. Neurol. 26, 719-723.
37. Pereverzev, M. O., Vygodina, T. V., Konstantinov, A. A., and Skulachev, V. P. (2003). Cytochrome c, an ideal antioxidant. Biochem. Soc. Trans. 31, 1312-1315.
38. Petroske, E., Meredith, G. E., Callen, S., Totterdell, S., and Lau, Y. S. (2001). Mouse model of Parkinsonism: a comparison between subacute MPTP and chronic MPTP/probenecid treatment. Neuroscience 106, 589-601.
39. Pothakos, K., Kurz, M. J., and Lau, Y. S. (2009). Restorative effect of endurance exercise on behavioral defi cits in the chronic mouse model of Parkinson's disease with severe neurodegeneration. BMC Neurosci. 10, 6.
40. Przedborski, S., and Jackson-Lewis, V. (1998). Mechanisms of MPTP toxicity. Mov. Disord. 13(Suppl. 1), 35-38.
41. Ramsay, R. R., and Singer, T. P. (1986). Energy-dependent uptake of Nmethyl-4-phenylpyridinium, the neurotoxic metabolite of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, by mitochondria. J. Biol. Chem. 261, 7585-7587.
42. Reeve, A. K., Krishnan, K. J., and Turnbull, D. (2008). Mitochondrial DNA mutations in disease, aging, and neurodegeneration. Ann. N. Y. Acad. Sci. 1147, 21-29.
43. Ricaurte, G. A., Irwin, I., Forno, L. S., DeLanney, L. E., Langston, E., and Langston, J. W. (1987). Aging and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced degeneration of dopaminergic neurons in the substantia nigra. Brain Res. 403, 43-51.
44. Schapira, A. H., Cooper, J. M., Dexter, D., Clark, J. B., Jenner, P., and Marsden, C. D. (1990). Mitochondrial complex I defi ciency in Parkinson's disease. J. Neurochem. 54, 823-827.
45. Schon, E. A., and Manfredi, G. (2003). Neuronal degeneration and mitochondrial dysfunction. J. Clin. Invest. 111, 303-312.
46. Sherer, T. B., Betarbet, R., and Greenamyre, J. T. (2002). Environment, mitochondria, and Parkinson's disease. Neuroscientist 8, 192-197.
47. Song, D. D., Shults, C. W., Sisk, A., Rockenstein, E., and Masliah, E. (2004). Enhanced substantia nigra mitochondrial pathology in human alpha- synuclein transgenic mice after treatment with MPTP. Exp. Neurol. 186, 158-172.
48. Sullivan, P. G., Geiger, J. D., Mattson, M. P., and Scheff, S. W. (2000). Dietary supplement creatine protects against traumatic brain injury. Ann. Neurol. 48, 723-729.
49. Swerdlow, R. H. (2009). The neurodegenerative mitochondriopathies. J. Alzheimers Dis. [Epub ahead of print].
50. Tieu, K., Perier, C., Caspersen, C., Teismann, P., Wu, D. C., Yan, S. D., Naini, A., Vila, M., Jackson-Lewis, V., Ramasamy, R., and Przedborski, S. (2003). D-beta-hydroxybutyrate rescues mitochondrial respiration and mitigates features of Parkinson disease. J. Clin. Invest. 112, 892-901.
51. Vila, M., and Przedborski, S. (2003). Targeting programmed cell death in neurodegenerative diseases. Nat. Rev. Neurosci. 4, 365-375.
52. Wallace, D. (1997). Mitochondrial DNA mutations and bioenergetic defects in aging and degenerative diseases. In The Molecular and Genetic Basis of Neurological Disease, Rosenberg, R. N., Prusiner, S. B., DiMauro, S., Barchi, R. L., eds (Boston, Butterworth-Heinemann), pp. 237-269.